PHIP

	ImmuneOnco Biopharmaceuticals (Shanghai) Inc. - B
	YOU SHOULD READ THE WARNING IN THE DOCUMENT.

► Warning ► Important ► Expected Timetable ► Contents ► Summary ► Definitions ► Glossary of Technical Terms ► Forward-Looking Statements ► Risk Factors ► Waivers from Strict Compliance with the Listing Rules and Exemption from Compliance with the Companies (Winding Up and Miscellaneous Provisions) Ordinance ► Information about This Document and the [REDACTED] ► Directors, Supervisors and Parties Involved in the [REDACTED] ► Corporate Information ► Industry Overview ► Regulatory Overview ► History, Development and Corporate Structure ► Business ► Relationship with Our Controlling Shareholders ► [REDACTED] ► Share Capital ► Substantial Shareholders ► Directors, Supervisors and Senior Management ► Financial Information ► Future Plans and Use of [REDACTED] ► [REDACTED] ► Structure of the [REDACTED] ► How to Apply for [REDACTED] ► Appendix IA - Accountants' Report ► Appendix IB - Unaudited Condensed Consolidated Financial Statements of the Group as of and for the Six Months Ended June 30, 2023 ► Appendix II - Unaudited [REDACTED] Financial Information ► Appendix III - Summary of Articles of Association ► Appendix IV - Statutory and General Information ► Appendix V - Documents Delivered to the Registrar of Companies in Hong Kong and Available on Display